Abstract
The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.
Original language | English |
---|---|
Pages (from-to) | 166-172 |
Number of pages | 7 |
Journal | Annals of Hematology |
Volume | 64 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 1992 |
Keywords
- Adult acute nonlymphocytic leukemia
- Chemotherapy
- Post-consolidation approaches
ASJC Scopus subject areas
- Hematology